Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bu Zhong Yi Qi Tang for Ocular Myasthenia Gravis
NCT06881173Recruiting
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of buzhong yiqi in myasthenia gravis (MG). Primary endpoint: Meridian energy at 12 weeks. Started Jun 2022; status: recruiting.
02
Drugs
buzhong yiqi
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06881173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881173.